These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 31066871)

  • 21. Losartan Versus Atenolol for Prevention of Aortic Dilation in Patients With Marfan Syndrome.
    Teixido-Tura G; Forteza A; Rodríguez-Palomares J; González Mirelis J; Gutiérrez L; Sánchez V; Ibáñez B; García-Dorado D; Evangelista A
    J Am Coll Cardiol; 2018 Oct; 72(14):1613-1618. PubMed ID: 30261963
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapies for Thoracic Aortic Aneurysms and Acute Aortic Dissections.
    Milewicz DM; Ramirez F
    Arterioscler Thromb Vasc Biol; 2019 Feb; 39(2):126-136. PubMed ID: 30651002
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Atenolol versus losartan in children and young adults with Marfan's syndrome.
    Lacro RV; Dietz HC; Sleeper LA; Yetman AT; Bradley TJ; Colan SD; Pearson GD; Selamet Tierney ES; Levine JC; Atz AM; Benson DW; Braverman AC; Chen S; De Backer J; Gelb BD; Grossfeld PD; Klein GL; Lai WW; Liou A; Loeys BL; Markham LW; Olson AK; Paridon SM; Pemberton VL; Pierpont ME; Pyeritz RE; Radojewski E; Roman MJ; Sharkey AM; Stylianou MP; Wechsler SB; Young LT; Mahony L;
    N Engl J Med; 2014 Nov; 371(22):2061-71. PubMed ID: 25405392
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A systematic review of the pharmacological management of aortic root dilation in Marfan syndrome.
    Thakur V; Rankin KN; Hartling L; Mackie AS
    Cardiol Young; 2013 Aug; 23(4):568-81. PubMed ID: 23083542
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characteristics of children and young adults with Marfan syndrome and aortic root dilation in a randomized trial comparing atenolol and losartan therapy.
    Lacro RV; Guey LT; Dietz HC; Pearson GD; Yetman AT; Gelb BD; Loeys BL; Benson DW; Bradley TJ; De Backer J; Forbus GA; Klein GL; Lai WW; Levine JC; Lewin MB; Markham LW; Paridon SM; Pierpont ME; Radojewski E; Selamet Tierney ES; Sharkey AM; Wechsler SB; Mahony L;
    Am Heart J; 2013 May; 165(5):828-835.e3. PubMed ID: 23622922
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Medical management of aortic disease in children with Marfan syndrome.
    Lindsay ME
    Curr Opin Pediatr; 2018 Oct; 30(5):639-644. PubMed ID: 30036202
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term clinical outcomes of losartan in patients with Marfan syndrome: follow-up of the multicentre randomized controlled COMPARE trial.
    van Andel MM; Indrakusuma R; Jalalzadeh H; Balm R; Timmermans J; Scholte AJ; van den Berg MP; Zwinderman AH; Mulder BJM; de Waard V; Groenink M
    Eur Heart J; 2020 Nov; 41(43):4181-4187. PubMed ID: 32548624
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Aortic root dilatation rate in pediatric patients with Marfan syndrome treated with losartan].
    Mariucci E; Guidarini M; Donti A; Lovato L; Wischmeijer A; Angeli E; Gargiulo GD; Picchio FM; Bonvicini M
    G Ital Cardiol (Rome); 2015 Dec; 16(12):690-5. PubMed ID: 26667946
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Distinct effects of losartan and atenolol on vascular stiffness in Marfan syndrome.
    Bhatt AB; Buck JS; Zuflacht JP; Milian J; Kadivar S; Gauvreau K; Singh MN; Creager MA
    Vasc Med; 2015 Aug; 20(4):317-25. PubMed ID: 25795452
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term doxycycline is more effective than atenolol to prevent thoracic aortic aneurysm in marfan syndrome through the inhibition of matrix metalloproteinase-2 and -9.
    Chung AW; Yang HH; Radomski MW; van Breemen C
    Circ Res; 2008 Apr; 102(8):e73-85. PubMed ID: 18388324
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of losartan vs. atenolol for the prevention of aortic dilation in Marfan syndrome: a randomized clinical trial.
    Forteza A; Evangelista A; Sánchez V; Teixidó-Turà G; Sanz P; Gutiérrez L; Gracia T; Centeno J; Rodríguez-Palomares J; Rufilanchas JJ; Cortina J; Ferreira-González I; García-Dorado D
    Eur Heart J; 2016 Mar; 37(12):978-85. PubMed ID: 26518245
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Investigation of Strategies to Block Downstream Effectors of AT1R-Mediated Signalling to Prevent Aneurysm Formation in Marfan Syndrome.
    Valdivia Callejon I; Buccioli L; Bastianen J; Schippers J; Verstraeten A; Luyckx I; Peeters S; Danser AHJ; Van Kimmenade RRJ; Meester J; Loeys B
    Int J Mol Sci; 2024 May; 25(9):. PubMed ID: 38732244
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transforming Growth Factor-β and the Renin-Angiotensin System in Syndromic Thoracic Aortic Aneurysms: Implications for Treatment.
    van Dorst DCH; de Wagenaar NP; van der Pluijm I; Roos-Hesselink JW; Essers J; Danser AHJ
    Cardiovasc Drugs Ther; 2021 Dec; 35(6):1233-1252. PubMed ID: 33283255
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aortic remodeling after transverse aortic constriction in mice is attenuated with AT1 receptor blockade.
    Kuang SQ; Geng L; Prakash SK; Cao JM; Guo S; Villamizar C; Kwartler CS; Peters AM; Brasier AR; Milewicz DM
    Arterioscler Thromb Vasc Biol; 2013 Sep; 33(9):2172-9. PubMed ID: 23868934
    [TBL] [Abstract][Full Text] [Related]  

  • 35. miR-29b participates in early aneurysm development in Marfan syndrome.
    Merk DR; Chin JT; Dake BA; Maegdefessel L; Miller MO; Kimura N; Tsao PS; Iosef C; Berry GJ; Mohr FW; Spin JM; Alvira CM; Robbins RC; Fischbein MP
    Circ Res; 2012 Jan; 110(2):312-24. PubMed ID: 22116819
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is losartan the true panacea for aneurysm disease? CON.
    Danyi P; Jovin IS
    Cardiol Clin; 2010 May; 28(2):279-85. PubMed ID: 20452542
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Atenolol versus Losartan in Marfan's Syndrome.
    Ziganshin BA; Mukherjee SK; Elefteriades JA
    N Engl J Med; 2015 Mar; 372(10):977-8. PubMed ID: 25738681
    [No Abstract]   [Full Text] [Related]  

  • 38. Atenolol versus Losartan in Marfan's Syndrome.
    Lacro RV; Dietz HC; Mahony L
    N Engl J Med; 2015 Mar; 372(10):980-1. PubMed ID: 25738680
    [No Abstract]   [Full Text] [Related]  

  • 39. Atenolol versus Losartan in Marfan's Syndrome.
    Treasure T; Pepper J; Mohiaddin R
    N Engl J Med; 2015 Mar; 372(10):978-9. PubMed ID: 25738682
    [No Abstract]   [Full Text] [Related]  

  • 40. Atenolol versus Losartan in Marfan's Syndrome.
    Mallat Z; Tedgui A
    N Engl J Med; 2015 Mar; 372(10):980. PubMed ID: 25738683
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.